Literature DB >> 24240973

Immunogenicity/hypersensitivity of biologics.

Michael W Leach1, James B Rottman, M Benjamin Hock, Deborah Finco, Jennifer L Rojko, Joseph C Beyer.   

Abstract

This continuing education course was designed to provide an overview of the immunologic mechanisms involved in immunogenicity and hypersensitivity reactions following administration of biologics in nonclinical toxicity studies, the methods used to determine whether such reactions are occurring, and the associated clinical and anatomic pathology findings. Hypersensitivity reactions have classically been divided into type I, II, III, and IV reactions; type I and III reactions are those most often observed following administration of biologics. A variety of methods can be used to detect these reactions. Antemortem methods include hematology; detection of antidrug antibodies, circulating immune complexes and complement fragments, and immunoglobulin E in serum; tests for serum complement activity; and evaluation of complement receptor 1 on erythrocytes. Postmortem methods include routine light microscopy and electron microscopy, which can demonstrate typical findings associated with hypersensitivity reactions, and immunohistochemistry, which can detect the presence of immune complexes in tissues, including the detection of the test article. A final determination of whether findings are related to a hypersensitivity reaction in individual animals or across the entire study should rely on the overall weight of evidence, as findings indicative of these reactions are not necessarily consistent across all affected animals.

Entities:  

Keywords:  antidrug antibodies; biologics; complement; drug development; electron microscopy; hypersensitivity; immunogenicity; immunohistochemistry.

Mesh:

Substances:

Year:  2013        PMID: 24240973     DOI: 10.1177/0192623313510987

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  18 in total

Review 1.  Advancements in Understanding Immunogenicity of Biotherapeutics in the Intraocular Space.

Authors:  Eric Wakshull; Valerie Quarmby; Hanns-Christian Mahler; Hongwen Rivers; Dhananjay Jere; Meg Ramos; Piotr Szczesny; Karoline Bechtold-Peters; Sharmila Masli; Swati Gupta
Journal:  AAPS J       Date:  2017-08-09       Impact factor: 4.009

2.  Risk of Hypersensitivity to Biologic Agents Among Medicare Patients With Rheumatoid Arthritis.

Authors:  Huifeng Yun; Fenglong Xie; Randall N Beyl; Lang Chen; James D Lewis; Kenneth G Saag; Jeffrey R Curtis
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-10       Impact factor: 4.794

3.  Development and Utility of an ELISA Method for Sensitive and Specific Detection of IgE Antidrug Antibodies.

Authors:  Zhandong Don Zhong; Lynn L Jiang; Puneet Khandelwal; Adam W Clarke; Ray Bakhtiar; Linglong Zou
Journal:  AAPS J       Date:  2020-01-29       Impact factor: 4.009

Review 4.  Roles of the first-generation claudin binder, Clostridium perfringens enterotoxin, in the diagnosis and claudin-targeted treatment of epithelium-derived cancers.

Authors:  Yosuke Hashimoto; Kiyohito Yagi; Masuo Kondoh
Journal:  Pflugers Arch       Date:  2016-09-15       Impact factor: 3.657

Review 5.  Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.

Authors:  Joachim R Kalden; Hendrik Schulze-Koops
Journal:  Nat Rev Rheumatol       Date:  2017-11-21       Impact factor: 20.543

6.  Neonatal Immune Tolerance Induction to Allow Long-Term Studies With an Immunogenic Therapeutic Monoclonal Antibody in Mice.

Authors:  Matthieu Piccand; Juliana Bessa; Eginhard Schick; Claudia Senn; Carole Bourquin; Wolfgang F Richter
Journal:  AAPS J       Date:  2015-11-24       Impact factor: 4.009

Review 7.  Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes.

Authors:  Murli Krishna; Steven G Nadler
Journal:  Front Immunol       Date:  2016-02-02       Impact factor: 7.561

8.  Type III hypersensitivity reactions to a B cell epitope antigen are abrogated using a depot forming vaccine platform.

Authors:  Lisa D MacDonald; Alecia MacKay; Valarmathy Kaliaperumal; Genevieve Weir; Andrea Penwell; Rajkannan Rajagopalan; Joanne M Langley; Scott Halperin; Marc Mansour; Marianne M Stanford
Journal:  Hum Vaccin Immunother       Date:  2017-10-30       Impact factor: 3.452

Review 9.  Biomarkers for nonclinical infusion reactions in marketed biotherapeutics and considerations for study design.

Authors:  Kirsten M Mease; Amy L Kimzey; Janice A Lansita
Journal:  Curr Opin Toxicol       Date:  2017-06

10.  Secukinumab, a novel anti-IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity.

Authors:  Anette Karle; Sebastian Spindeldreher; Frank Kolbinger
Journal:  MAbs       Date:  2016-01-28       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.